Protocol Ledger

NCT06988475 · Phase II/III · RECRUITING

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

Interventional Phase II/III clinical trial protocol NCT06988475 sponsored by Cancer Research UK in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-19 Enrollment: 30 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06988475
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)30 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06988475
Protocol FieldVerified Registry Value
NCT IdentifierNCT06988475
Consolidated Lead SponsorCancer Research UK
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment30 participants (ESTIMATED)
Registered Start Date2024-11-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06988475
Hospital Research SiteLocationSite Profile
Addenbrooke's HospitalCambridge, United KingdomOpen Hospital Dossier ->
Western General HospitalEdinburgh, United KingdomOpen Hospital Dossier ->
Leicester Royal InfirmaryLeicester, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI